SCHOTT Pharma AG & Co. KGaA/€1SXP

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About SCHOTT Pharma AG & Co. KGaA

SCHOTT Pharma AG & Co. KGaA specializes in the design and manufacture of drug containment and delivery solutions for injectable medications, including prefillable glass and polymer syringes, cartridges, vials, and ampoules. Established as a standalone entity in August 2022 following its separation from SCHOTT AG, the company is headquartered in Mainz, Germany, and operates 16 manufacturing sites across Europe, North and South America, and Asia. With a portfolio of over 1,000 patents and a dedicated R&D center in Switzerland, SCHOTT Pharma focuses on developing innovative solutions to meet the evolving needs of the pharmaceutical industry. The company serves over 1,800 customers, including the top 30 pharmaceutical manufacturers for injectable drugs, and reported revenues of €821 million in the fiscal year 2022. SCHOTT Pharma is committed to sustainable development, aiming to achieve climate neutrality by 2030.

Ticker

€1SXP

Primary listing

XETRA

Industry

Life Sciences Tools & Services
Headquarters

Employees

4,790

ISIN

DE000A3ENQ51

1SXP Metrics

BasicAdvanced
€4B
27.37
€0.98
-
€0.16
0.60%

Bulls say / Bears say

SCHOTT Pharma's Drug Delivery Systems (DDS) segment achieved a 39% year-over-year revenue increase in Q3 2024, indicating strong demand for their products. (gurufocus.com)
The company raised its full-year revenue growth guidance for fiscal year 2024 from 9%-11% to 11%-13%, reflecting confidence in sustained growth. (gurufocus.com)
SCHOTT Pharma's High-Value Solutions (HVS) revenue share reached 53% in the first nine months of 2024, aligning with its midterm goal of over 60%, suggesting a successful strategic shift towards higher-margin products. (gurufocus.com)
SCHOTT Pharma anticipates slower growth in fiscal year 2025 due to reduced syringe demand from a major customer, which could impact overall revenue. (finanzwire.com)
BofA Securities lowered its price target for SCHOTT Pharma shares from €45 to €35, citing tempered expectations for sales growth and EBITDA margins for fiscal year 2025. (investing.com)
The company faces ongoing underutilization in certain production areas, such as vials, which may affect profitability if not addressed promptly. (gurufocus.com)
Data summarised monthly by Lightyear AI. Last updated on 27 Jun 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €1SXP

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs